Systematic review (3 studies) RA pts shows bariatric surgery (n=6700) can significantly lower disease activity at 12 mos and reduce comorbidities (OR=0.45) and in-hospital mortality (OR=0.41). BMI at baseline and after BS was 43.1 & 29.7kg/m2, respectively https://t.co/3Uweb5spGC https://t.co/2TAA2ppZpy

RCT 114 fibromyalgia pts Rx w/ cognitive behavioral Tx (CBT) vs control education. CBT had significant reduction in pain catastrophizing, pain interference & Sxs w/ improved function; neuroimaging in 98 pts also showed comparable improvement https://t.co/bKwREZdDF0 https://t.co/XkZJAMBfld

Polands disease study (sarcoidosis 78.6K; #AOSD 3294; systemic sclerosis 35.5K) betw 2009-2018. Avg hospitalization was 5.39 days sarcoidosis, 6.22 days scleroderma, & 7.44 days for Still’s (latter decr 11.7 to 5.8, betw 2008-2014) https://t.co/OcNzt7IKC5 https://t.co/uPcbOyizQN

Naltrexone was NOT superior to placebo in a blinded RCT of 99 Fibromyalgia pts. Pain decreased –1·3 points w/ NAL vs –0·9 in PBO (p=0·27). D/C were similar (8% vs 6%). NAL may improve improve memory problems in FM pts. https://t.co/5i98Jr4u84 https://t.co/SkEbLaMfvI

Post-Menopausal Osteoporosis Review and Recommendations A recent New England Journal review of post-menopausal osteoporosis (OP) provided updated information, strategies and a review of guidelines and clinical recommendations. https://t.co/GJzR7q82si https://t.co/DOA4G1fQlV

Proof-of-concept, open label study of 30 #GCA pts (mean age 74 yrs) Rx w/ 12 mos of weekly tocilizumab & 8wks of prednisone. At wk 52 77% were in sustained pred-free remission & 23% relapsed at mean 16 wks (none w/ visual loss) https://t.co/Tbwhqs91Mf https://t.co/kZWkp5g87m

No difference in SIE/hospitalized infxn in #RA Tx w/ ABAtacept, csDMARDs or other b/tsDMARDs - from 5 data sets (2 biologic registries, NDB, 2 claims databases). IRs per 1000PYs: ABA (16-56), csDMARDs (19-46), b/tsDMARDs (18-40). No diff in OI https://t.co/WaPUNHJb76 https://t.co/uXWe7LDLpJ

Difficult-to-treat (D2T) axSpA seen in 88/311 axSpA pts. D2T axSpA= failure of ≥2 b/tsDMARDs (Very D2T-axSpA: same in <2yrs). D2T had signif more periph arthritis (35 vs 21%), higher BASDAI (64 v 59) & more FM. Very D2T had more CRP, IBD, no FM https://t.co/DnxxypAEqo https://t.co/B5TxvDoYy4

"The speed of our forward motion is directly related to the velocity of the people around us." - Seth Godin https://t.co/9Abzj19Hp9 https://t.co/FxitvtO6sl

Metanalysis (60 RCTs; 20,418 SpA & PsA pts Rx 17 b/tsDMARDs) shows increased NonSerious infections (RR 1.15), @higher doses, longer Rx; mainly URI & ENT infxn, Signif for axSpA (RR 1.32), not PsA(RR 1.05). SIE were NOT increased https://t.co/Ab9Q9NRFu3 https://t.co/Gzoe3sRaXp

Swedish registry shows #PsA mortality risk ~11% (HR 1.11) higher than general pop., driven by comorbidity, esp in women (HR: 1.23) w/ longer Dz duration (HR: 1.18). Causes of death lead by CV Dz and malignancy. https://t.co/M6muM2UIkN https://t.co/az3kig9pBu

Here’s what will change my practice in Rheumatoid Arthritis https://t.co/7L1QFSVzpe https://t.co/hmR3VOyKls